Next-generation vaccines to prevent AMR

To limit the spread of AMR pathogens, preventing illnesses is a key part of our strategy. Our technology involves use of patient-derived antibodies to identify potential vaccine antigens.

Antigens identified via this route are already known to be functionally-immunogenic in humans. Also, another huge benefit is the the potential created for the generation of chimeric multi-epitope variants.

  • Infection prevention
  • Antimicrobial stewardship
  • Microbial diagnostics
  • Antimicrobial compound/strategy
  • Removal antibiotics/bacteria

  • Bacteria
  • Viruses
  • Fungi
  • Yeasts
  • Parasites

  • Human
  • Veterinary
  • AgriFood
  • Environmental
  • Other

Development stage:
  • Research
  • Development
  • Validation
  • Market entry
  • Marketed product

  • Academia
  • Company
  • Institute
  • NGO
  • Government

  • Co-develop
  • License
  • Outsource
  • Joint Venture
  • Sell

Funding organisation:
  • CARB-X
  • FIND
  • OTHER / NA

Infectious disease area:
  • UTI
  • STI
  • RTI
  • BSI
  • GII
  • SSTI
  • CNSI
  • IAI
  • SSI

Geographic origin:
  • Eurasia
  • North America
  • South America
  • Africa
  • Oceania

Imperial College London is a world top ten university renowned for its excellent teaching and research. Rated highly globally, Imperial strives to cultivate the next generation of scholars, scientists and teachers through interdisciplinary collaboration. Situated in London, the college is an environment for education, research, translating and commercializing scientific discoveries to address global problems.

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed